328 related articles for article (PubMed ID: 29752258)
1. How and when I do allogeneic transplant in CLL.
Gribben JG
Blood; 2018 Jul; 132(1):31-39. PubMed ID: 29752258
[TBL] [Abstract][Full Text] [Related]
2. Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape.
Iovino L; Shadman M
Curr Treat Options Oncol; 2020 Mar; 21(4):24. PubMed ID: 32170458
[TBL] [Abstract][Full Text] [Related]
3. Current Treatment of Refractory/Relapsed Chronic Lymphocytic Leukemia: A Focus on Novel Drugs.
Smolewski P; Robak T
Acta Haematol; 2021; 144(4):365-379. PubMed ID: 33238270
[TBL] [Abstract][Full Text] [Related]
4. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.
Kharfan-Dabaja MA; Kumar A; Hamadani M; Stilgenbauer S; Ghia P; Anasetti C; Dreger P; Montserrat E; Perales MA; Alyea EP; Awan FT; Ayala E; Barrientos JC; Brown JR; Castro JE; Furman RR; Gribben J; Hill BT; Mohty M; Moreno C; O'Brien S; Pavletic SZ; Pinilla-Ibarz J; Reddy NM; Sorror M; Bredeson C; Carpenter P; Savani BN
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2117-2125. PubMed ID: 27660167
[TBL] [Abstract][Full Text] [Related]
5. Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia.
Dreger P; Montserrat E
Leukemia; 2002 Jun; 16(6):985-92. PubMed ID: 12040430
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia.
Hill BT; Ahn KW; Hu ZH; Aljurf M; Beitinjaneh A; Cahn JY; Cerny J; Kharfan-Dabaja MA; Ganguly S; Ghosh N; Grunwald MR; Inamoto Y; Kindwall-Keller T; Nishihori T; Olsson RF; Saad A; Seftel M; Seo S; Szer J; Tallman M; Ustun C; Wiernik PH; Maziarz RT; Kalaycio M; Alyea E; Popat U; Sobecks R; Saber W
Biol Blood Marrow Transplant; 2018 Mar; 24(3):581-586. PubMed ID: 29032274
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies.
Rafei H; Kharfan-Dabaja MA
Hematol Oncol Stem Cell Ther; 2018 Mar; 11(1):1-12. PubMed ID: 28549767
[TBL] [Abstract][Full Text] [Related]
8. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
Hallek M
Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
[TBL] [Abstract][Full Text] [Related]
9. CAR T-cell therapy for CLL: a new addition to our treatment toolbox?
Iovino L; Shadman M
Clin Adv Hematol Oncol; 2023 Mar; 21(3):134-141. PubMed ID: 36867557
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
[TBL] [Abstract][Full Text] [Related]
11. Stem-cell transplantation for chronic lymphocytic leukemia: the 1999 perspective.
Dreger P; Michallet M; Schmitz N
Ann Oncol; 2000; 11 Suppl 1():49-53. PubMed ID: 10707779
[TBL] [Abstract][Full Text] [Related]
12. The evolving role of hematopoietic cell transplantation in chronic lymphocytic leukemia.
Davids MS; Alyea EP
Curr Hematol Malig Rep; 2015 Mar; 10(1):18-27. PubMed ID: 25682168
[TBL] [Abstract][Full Text] [Related]
13. Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia.
Shustik C; Bence-Bruckler I; Delage R; Owen CJ; Toze CL; Coutre S
Ann Hematol; 2017 Jul; 96(7):1185-1196. PubMed ID: 28389687
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia.
Moreno C; Villamor N; Colomer D; Esteve J; Martino R; Nomdedéu J; Bosch F; López-Guillermo A; Campo E; Sierra J; Montserrat E
J Clin Oncol; 2005 May; 23(15):3433-8. PubMed ID: 15809449
[TBL] [Abstract][Full Text] [Related]
15. [Advances in the treatment of chronic lymphocytic leukaemia].
Mozas P; Delgado J
Med Clin (Barc); 2016 Nov; 147(10):447-454. PubMed ID: 27431885
[TBL] [Abstract][Full Text] [Related]
16. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
[TBL] [Abstract][Full Text] [Related]
17. Current state of hematopoietic cell transplantation in CLL as smart therapies emerge.
Kharfan-Dabaja MA; El-Asmar J; Awan FT; Hamadani M; Ayala E
Best Pract Res Clin Haematol; 2016 Mar; 29(1):54-66. PubMed ID: 27742072
[TBL] [Abstract][Full Text] [Related]
18. Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia.
Algrin C; Golmard JL; Michallet M; Reman O; Huynh A; Perrot A; Sirvent A; Plesa A; Salaun V; Béné MC; Bories D; Tournilhac O; Merle-Béral H; Leblond V; Le Garff-Tavernier M; Dhedin N
Eur J Haematol; 2017 Apr; 98(4):363-370. PubMed ID: 27943415
[TBL] [Abstract][Full Text] [Related]
19. The Difficult-to-Treat del 17 p Patient-A Case Report in Chronic Lymphocytic Leukemia.
Moldovianu AM; Crisan AM; Varady Z; Coriu D
Medicina (Kaunas); 2021 Dec; 58(1):. PubMed ID: 35056341
[TBL] [Abstract][Full Text] [Related]
20. Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?
McClanahan F; Gribben J
Hematol Oncol Clin North Am; 2014 Dec; 28(6):1055-71. PubMed ID: 25459179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
